3.84
+0.0487(+1.28%)
Currency In USD
| Previous Close | 3.79 |
| Open | 3.68 |
| Day High | 3.92 |
| Day Low | 3.68 |
| 52-Week High | 92.4 |
| 52-Week Low | 2.36 |
| Volume | 65,624 |
| Average Volume | 1.67M |
| Market Cap | 2.74M |
| PE | 0.09 |
| EPS | 41.76 |
| Moving Average 50 Days | 4.45 |
| Moving Average 200 Days | 7.99 |
| Change | 0.05 |
If you invested $1000 in Psyence Biomedical Ltd. Common Shares (PBM) since IPO date, it would be worth $1.03 as of September 17, 2025 at a share price of $3.839. Whereas If you bought $1000 worth of Psyence Biomedical Ltd. Common Shares (PBM) shares 1 year ago, it would be worth $1.03 as of September 17, 2025 at a share price of $3.839.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025
Newsfile
Jun 18, 2025 12:30 PM GMT
Investors, Entrepreneurs, and Industry Experts to Convene at the Premier Psychedelic Science Business Forum hosted by Multidisciplinary Association for Psychedelic Studies (MAPS)Denver, Colorado--(Newsfile Corp. - June 18, 2025) - Psyence Biomedical
Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements
Newsfile
Jun 17, 2025 12:00 PM GMT
New York, New York--(Newsfile Corp. - June 17, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced that it has received formal notification from the Nasdaq Hearings Panel confirming that the Company has r
Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial
Newsfile
May 27, 2025 11:30 AM GMT
New York, New York--(Newsfile Corp. - May 27, 2025) - Psyence BioMed (NASDAQ: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company developing nature-derived psilocybin therapies for unmet mental health needs, today announced the fina